These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort. Hirtz C; Busto GU; Bennys K; Kindermans J; Navucet S; Tiers L; Lista S; Vialaret J; Gutierrez LA; Dauvilliers Y; Berr C; Lehmann S; Gabelle A Alzheimers Res Ther; 2023 Feb; 15(1):34. PubMed ID: 36800984 [TBL] [Abstract][Full Text] [Related]
6. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Kapaki E; Paraskevas GP; Zalonis I; Zournas C Eur J Neurol; 2003 Mar; 10(2):119-28. PubMed ID: 12603286 [TBL] [Abstract][Full Text] [Related]
8. The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia. Santangelo R; Dell'Edera A; Sala A; Cecchetti G; Masserini F; Caso F; Pinto P; Leocani L; Falautano M; Passerini G; Martinelli V; Comi G; Perani D; Magnani G Curr Alzheimer Res; 2019; 16(7):587-595. PubMed ID: 31345148 [TBL] [Abstract][Full Text] [Related]
9. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
10. Multiplexed femtomolar detection of Alzheimer's disease biomarkers in biofluids using a reduced graphene oxide field-effect transistor. Park D; Kim JH; Kim HJ; Lee D; Lee DS; Yoon DS; Hwang KS Biosens Bioelectron; 2020 Nov; 167():112505. PubMed ID: 32841782 [TBL] [Abstract][Full Text] [Related]
11. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. West T; Kirmess KM; Meyer MR; Holubasch MS; Knapik SS; Hu Y; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE Mol Neurodegener; 2021 May; 16(1):30. PubMed ID: 33933117 [TBL] [Abstract][Full Text] [Related]
12. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
13. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543 [TBL] [Abstract][Full Text] [Related]
15. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease. Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652 [TBL] [Abstract][Full Text] [Related]
16. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867 [TBL] [Abstract][Full Text] [Related]
17. Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer's disease. Jia L; Zhu M; Yang J; Pang Y; Wang Q; Li Y; Li T; Li F; Wang Q; Li Y; Wei Y BMC Med; 2021 Nov; 19(1):264. PubMed ID: 34775974 [TBL] [Abstract][Full Text] [Related]
18. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data. Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048 [TBL] [Abstract][Full Text] [Related]
19. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248 [TBL] [Abstract][Full Text] [Related]
20. Amyloid-β protein and MicroRNA-384 in NCAM-Labeled exosomes from peripheral blood are potential diagnostic markers for Alzheimer's disease. Li Y; Meng S; Di W; Xia M; Dong L; Zhao Y; Ling S; He J; Xue X; Chen X; Liu C CNS Neurosci Ther; 2022 Jul; 28(7):1093-1107. PubMed ID: 35470961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]